TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: The ECHELON-2 study demonstrated the clinical benefit of adding brentuximab vedotin to CHOP-based chemotherapy for the frontline treatment of patients with CD30-positive PTCL, but further research is being conducted to build upon this therapeutic advance.